Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Ball

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Transplantation and Cellular Therapy|May 14, 2023
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisJanny M Yao, Salman Otoukesh, Hanna Kim, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Transplantation and Cellular Therapy|January 22, 2023
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation InotuzumabVaibhav Agrawal, Hoda Pourhassan, Ni-Chun Tsai, et al.
Transplantation and Cellular Therapy|July 5, 2025
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal ImpairmentTina Nguyen, Tanya Markary, Ni-Chun Tsai, et al.
Blood Advances|January 17, 2025
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALLIbrahim Aldoss, Shanpeng Li, Jianying Zhang, et al.
American Journal of Hematology|March 7, 2023
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusionsIbrahim Aldoss, Michelle Afkhami, Dongyun Yang, et al.
Frontiers in Immunology|March 7, 2025
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxisDiana T Samuels, Janny M Yao, Yazeed Samara, et al.
Transplantation and Cellular Therapy|March 30, 2026
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell TransplantationJorge M Ramos Perez, Haoyue Shan, Dongyun Yang, et al.
Haematologica|November 7, 2024
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaIbrahim Aldoss, Jianying Zhang, Kathryn Shimamoto, et al.
Vaccines|September 28, 2023
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular TherapyFlavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Transplantation and Cellular Therapy|May 14, 2023
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisJanny M Yao, Salman Otoukesh, Hanna Kim, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Transplantation and Cellular Therapy|January 22, 2023
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation InotuzumabVaibhav Agrawal, Hoda Pourhassan, Ni-Chun Tsai, et al.
Transplantation and Cellular Therapy|July 5, 2025
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal ImpairmentTina Nguyen, Tanya Markary, Ni-Chun Tsai, et al.
Blood Advances|January 17, 2025
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALLIbrahim Aldoss, Shanpeng Li, Jianying Zhang, et al.
American Journal of Hematology|March 7, 2023
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusionsIbrahim Aldoss, Michelle Afkhami, Dongyun Yang, et al.
Frontiers in Immunology|March 7, 2025
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxisDiana T Samuels, Janny M Yao, Yazeed Samara, et al.
Transplantation and Cellular Therapy|March 30, 2026
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell TransplantationJorge M Ramos Perez, Haoyue Shan, Dongyun Yang, et al.
Haematologica|November 7, 2024
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaIbrahim Aldoss, Jianying Zhang, Kathryn Shimamoto, et al.
Vaccines|September 28, 2023
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular TherapyFlavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, et al.
Pageof 6